Vichy Laboratoires Normaderm Bha Exfoliating Acne Treatment

Description

The product is identified by the SPL code 34089-3. No specific description details are provided in the available data.

Uses and Indications

This drug is indicated for the treatment of acne. It effectively clears acne blemishes and facilitates the healing of the skin. Additionally, it helps prevent the formation of new acne blemishes.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Healthcare professionals are advised to cleanse the skin thoroughly prior to the application of this product. The affected area should be covered with a thin layer of the formulation. Initial dosing should consist of one application daily, with the possibility of increasing to two or three times daily based on clinical response or as directed by a physician.

It is important to monitor for signs of excessive dryness or peeling. Should these adverse effects occur, the frequency of application should be reduced to once daily or every other day to mitigate discomfort.

Contraindications

Use is contraindicated in the event of accidental ingestion; immediate medical assistance or contact with a Poison Control Center is required. Additionally, if irritation occurs, the concurrent use of multiple topical acne medications is contraindicated to prevent exacerbation of skin irritation.

Warnings and Precautions

For external use only. This product is intended solely for topical application and should not be ingested. In the event of accidental ingestion, immediate medical assistance should be sought, or the local Poison Control Center should be contacted without delay.

Skin irritation and dryness may occur, particularly when this product is used concurrently with other topical acne medications. To minimize the risk of adverse effects, it is recommended that only one topical acne treatment be utilized at a time. Healthcare professionals should monitor patients for signs of irritation and advise them to discontinue use if such symptoms arise.

In the absence of specific instructions regarding discontinuation, healthcare providers should exercise clinical judgment and advise patients to consult their physician if they experience any concerning symptoms or reactions.

Side Effects

For external use only. No specific side effects or adverse reactions have been identified in clinical trials or postmarketing experiences. Patients should be advised to use the product as directed and to report any unexpected reactions to their healthcare provider.

Drug Interactions

The concurrent use of multiple topical acne medications may increase the risk of skin irritation and dryness. To mitigate this risk, it is advised that only one topical acne medication be used at a time. If irritation occurs, discontinuation of one of the medications is recommended to allow the skin to recover. Monitoring for signs of irritation is essential when initiating or adjusting treatment regimens involving topical acne therapies.

Packaging & NDC

Below are the non-prescription pack sizes of Vichy Laboratoires Normaderm Bha Exfoliating Acne Treatment (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance or contact with a Poison Control Center is recommended.

For topical application, it is advised to initiate treatment with one application daily. Dosage may be gradually increased to two or three times daily as needed or as directed by a healthcare professional. Care should be taken to monitor for excessive drying of the skin; if bothersome dryness or peeling occurs, the frequency of application should be reduced to once a day or every other day.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

The safety of salicylic acid during pregnancy has not been established. Salicylic acid is contraindicated in pregnancy due to potential risks to the fetus, including the risk of teratogenic effects associated with its use. Pregnant women should avoid using this product unless directed by a healthcare provider. It is essential for healthcare professionals to counsel pregnant patients regarding these risks and to consider alternative treatments when necessary.

Lactation

There are no specific warnings or recommendations regarding the use of this product in nursing mothers. Additionally, there is no information available about the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and ensuring adequate circulation. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and is deemed appropriate based on clinical judgment.

Additionally, it is crucial to consult local poison control centers or relevant toxicology resources for guidance on specific management protocols and antidotes, if applicable. Continuous monitoring and supportive care remain the cornerstone of managing overdose situations until the patient stabilizes or further interventions are deemed necessary.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the medication is swallowed. It is crucial for patients to understand the potential risks associated with accidental ingestion.

Additionally, healthcare providers should inform patients about the likelihood of skin irritation and dryness when using this medication in conjunction with other topical acne treatments. Patients should be counseled to use only one topical acne medication at a time to minimize the risk of irritation. This guidance is essential for ensuring the safe and effective use of the medication.

Storage and Handling

The product is classified as flammable until dry. It is essential to keep the product away from flames and heat sources to ensure safe handling and storage. Proper precautions should be taken to minimize the risk of ignition during use and storage.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Vichy Laboratoires Normaderm Bha Exfoliating Acne Treatment, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)